Eliem Therapeutics Inc (ELYM)
7.59
-0.07
(-0.91%)
USD |
NASDAQ |
May 31, 16:00
7.68
+0.09
(+1.19%)
After-Hours: 20:00
Eliem Therapeutics Cash from Financing (Quarterly): 0.015M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 0.015M |
| December 31, 2023 | 0.288M |
| September 30, 2023 | 0.528M |
| June 30, 2023 | 0.024M |
| March 31, 2023 | 0.001M |
| December 31, 2022 | 0.00 |
| September 30, 2022 | 0.00 |
| June 30, 2022 | 0.00 |
| March 31, 2022 | 0.00 |
| Date | Value |
|---|---|
| December 31, 2021 | 0.038M |
| September 30, 2021 | 83.14M |
| June 30, 2021 | 59.97M |
| March 31, 2021 | 34.08M |
| December 31, 2020 | 4.925M |
| September 30, 2020 | 0.00 |
| June 30, 2020 | 0.00 |
| March 31, 2020 | 0.00 |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
--
Minimum
Mar 2020
83.14M
Maximum
Sep 2021
10.77M
Average
0.015M
Median
Mar 2024
Cash from Financing (Quarterly) Benchmarks
| Alpine Immune Sciences Inc (DELISTED) | 19.35M |
| Candel Therapeutics Inc | -1.255M |
| Cyclacel Pharmaceuticals Inc | -0.079M |
| Lipocine Inc | -0.0081M |
| GlycoMimetics Inc | 0.0049M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -1.819M |
| Cash from Investing (Quarterly) | 13.75M |
| Free Cash Flow | -7.241M |
| Free Cash Flow Per Share (Quarterly) | -0.0658 |
| Free Cash Flow Yield | -3.50% |